Journal: Journal of the neurological sciences

Loading...

Abbreviation

J Neurol Sci

Publisher

Elsevier

Journal Volumes

ISSN

0022-510X
1878-5883

Description

Search Results

Publications 1 - 5 of 5
  • Zhang, Zhiqiang; Liao, Wei; Wang, Zhengge; et al. (2014)
    Journal of the neurological sciences
  • Levi, Ofir; Jongen-Relob, Ana L.; Feldon, Joram; et al. (2005)
    Journal of the neurological sciences
  • Kong, Yanyan; Cao, Lei; Wang, Jiao; et al. (2024)
    Journal of the neurological sciences
    Background: Reactive astrocytes play an important role in the development of Alzheimer's disease and primary tauopathies. Here, we aimed to investigate the relationships between reactive astrocytes. Microgliosis and glucose metabolism with Tau and amyloid beta pathology by using multi-tracer imaging in widely used tauopathy and familial Alzheimer's disease mouse models. Results: Positron emission tomography imaging using [¹⁸F]PM-PBB3 (tau), [¹⁸F]florbetapir (amyloid-beta), [¹⁸F]SMBT-1 (monoamine oxidase-B), [¹⁸F]DPA-714 (translocator protein) and [¹⁸F]fluorodeoxyglucose was carried out in 3- and 7-month-old rTg4510 tau mice, 5 × FAD familial Alzheimer's disease mice and wild-type mice. Immunofluorescence staining was performed to validate the pathological distribution in the mouse brain after in vivo imaging. We found increased regional levels of [¹⁸F]PM-PBB3, [¹⁸F]SMBT-1, and [¹⁸F]DPA-714 and hypoglucose metabolism in the brains of 7-month-old rTg4510 mice compared to age-matched wild-type mice. Increased [¹⁸F]SMBT-1 uptake was observed in the brains of 3, 7-month-old 5 × FAD mice, with elevated regional [¹⁸F]florbetapir and [¹⁸F]DPA-714 uptakes in the brains of 7-month-old 5 × FAD mice, compared to age-matched wild-type mice. Positive correlations were shown between [¹⁸F]SMBT-1 and [¹⁸F]PM-PBB3, [¹⁸F]DPA-714 and [¹⁸F]PM-PBB3 in rTg4510 mice, and between [¹⁸F]florbetapir and [¹⁸F]DPA-714 SUVRs in 5 × FAD mice. Conclusion: In summary, these findings provide in vivo evidence that reactive astrocytes, microglial activation, and cerebral hypoglucose metabolism are associated with tau and amyloid pathology development in animal models of tauopathy and familial Alzheimer's disease.
  • Gagnon, Cynthia; Lavoie, Caroline; Lessard, Isabelle; et al. (2014)
    Journal of the neurological sciences
  • Kanzler, Christoph; Lessard, Isabelle; Gassert, Roger; et al. (2023)
    Journal of the neurological sciences
    Objective Adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) often present with reduced upper limb coordination affecting their independence in daily life. Previous studies in ARSACS identified reduced performance in clinical assessments requiring fine and gross dexterity as well as prehension. However, the kinematic and kinetic aspects underlying reduced upper limb coordination in ARSACS have not been systematically investigated yet. In this work, we aimed to provide a detailed characterization of alterations in upper limb movement patterns and hand grip forces in 57 participants with ARSACS. Methods We relied on a goal-directed technology-aided assessment task, which provides eight previously validated digital health metrics describing movement efficiency, smoothness, speed, and grip force control. Results First, we observed that 98.3% of the participants were impaired in at least one of the metrics, that all metrics are significantly impaired on a population level, and that grip force control during precise manipulations is most commonly and strongly impaired. Second, we identified high inter-participant variability in the kinematic and kinetic impairment profiles, thereby capturing different clinical profiles subjectively observed in this population. Lastly, abnormal goal-directed task performance in ARSACS could be best explained by reduced movement speed, efficiency, and especially force control during precise manipulations, while abnormal movement smoothness did not have a significant effect. Interpretation This work helped to refine the clinical profile of ARSACS and highlights the need for characterizing individual kinematic and kinetic impairment profiles in clinical trials in ARSACS.
Publications 1 - 5 of 5